Suppr超能文献

在使用苯扎贝特治疗高甘油三酯血症患者期间,骨骼肌组织中脂蛋白脂肪酶活性升高。

Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.

作者信息

Vessby B, Lithell H, Ledermann H

出版信息

Atherosclerosis. 1982 Jul;44(1):113-8. doi: 10.1016/0021-9150(82)90057-0.

Abstract

Eleven hypertriglyceridaemic patients were treated with 600 mg bezafibrate daily for 2 months. The mean serum triglyceride concentration decreased by 35% (P less than 0.01) corresponding to a reduction in the very low density lipoprotein triglycerides by 41% (P less than 0.01). The high density lipoprotein cholesterol concentration and the serum concentration of apolipoproteins AI and AII increased by 19% (P less than 0.02), 11% (N.S., P less than 0.08) and 24% (P less than 0.01), respectively. The fractional removal rate (K2) in the intravenous fat tolerance test (IVFTT) increased by 37% (P less than 0.001). This was associated with significant increase of the skeletal muscle lipoprotein lipase activity ( + 39%, P less than 0.05). The mean value for the adipose tissue lipoprotein lipase activity remained unchanged. The K2 at IVFTT was correlated highly significantly to the activity of skeletal muscle lipoprotein lipase (r = 0.85, P less than 0.01). The present study indicates that the main reason for the reduction of the serum triglycerides during treatment with bezafibrate may be an increased activity of the skeletal muscle tissue lipoprotein lipase activity.

摘要

11名高甘油三酯血症患者每天服用600毫克苯扎贝特,持续2个月。血清甘油三酯平均浓度下降了35%(P<0.01),相应地极低密度脂蛋白甘油三酯下降了41%(P<0.01)。高密度脂蛋白胆固醇浓度以及载脂蛋白AI和AII的血清浓度分别升高了19%(P<0.02)、11%(无统计学意义,P<0.08)和24%(P<0.01)。静脉脂肪耐量试验(IVFTT)中的分数清除率(K2)提高了37%(P<0.001)。这与骨骼肌脂蛋白脂肪酶活性显著增加有关(增加39%,P<0.05)。脂肪组织脂蛋白脂肪酶活性的平均值保持不变。IVFTT时的K2与骨骼肌脂蛋白脂肪酶活性高度显著相关(r = 0.85,P<0.01)。本研究表明,苯扎贝特治疗期间血清甘油三酯降低的主要原因可能是骨骼肌组织脂蛋白脂肪酶活性增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验